The Prima System is intended to partially replace the normal physiological function of the eyes photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve.

Commercial Partners

• Pixium Vision

  Paris, France

Academic Collaborators

• Palanker Lab

  Stanford University

Milestones

• 2023: FDA approval

Background

The Prima System aims to elicit functional artificial, or bionic, vision in the form of light perception replacing partially the natural central vision loss. The Prima System is composed of three main elements: Wireless retinal implant, pair of glasses with a camera and digital projector, and a pocket processor. It was approved by the FDA in 2023 for implantation in human patients with atrophic dry age-related macular degeneration (AMD) with the goal of partially restoring their vision.

Device Specifications

• Number of electrodes: 378

Clinical Trials

• NCT03333954
• NCT03392324